SMMT · Summit Therapeutics
Conviction · Medium · more likely to lead the S&P 500 over the next three months, by a modest margin
Wrong if: a weekly close below $13.00
Note written ·
Price against the kill line
8.8% clear of its kill line on the 13 November 2026 close.
How to read this
The red mark is the price level of the published kill line: a close through it (a weekly close, on a weekly line) would prove the research note wrong on price. The dot is where the stock closed on 13 November 2026; a dot left of the mark has closed through its line.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a weekly close below $13.00, on record since 11 November 2026; only a weekly close settles it. The shares are up 10.7% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A weekly close below $13.00, under the $14.19 close of 5 November 2026 and the $14.50 close of 26 October 2026, which would show the market pricing a failed review. An FDA complete response letter or review extension for ivonescimab would also break the approval case.
Research onlyNot in the portfolio.
Last catalyst
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 4 November 2026; valuation at the 13 November 2026 close
- Free cash flow, four quarters ($M)
- −527
- Net cash, cash less debt ($M)
- 630
- Free-cash-flow yield (%)
- −4.7
All filed numbers
What Summit Therapeutics reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Pre-tax income ($M) | Not reported |
| Net income ($M) four quarters: −833 | −208 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +7.4 |
| Operating cash flow ($M) | −525 |
| Capital spending ($M) | 1.7 |
| Free cash flow ($M) | −527 |
| Cash and short-term investments ($M) | 630 |
| Debt ($M) | None reported |
| Net cash, cash less debt ($M) no debt reported | 630 |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | Not reported |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | 565 |
| Market value ($M) | 11,317 |
| Enterprise value, market value plus net debt ($M) no debt reported | 10,687 |
| Enterprise value to sales (×) | Not available |
| Enterprise value to operating income (×) | Not available |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 20.0 |
| Free-cash-flow yield (%) | −4.7 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 5.1% of shares outstanding sold short, 7.0 days of average trading to cover, −0.6% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $0 |
| 12 monthsfrom | $52.2M | $0 |
The thesis
Summit Therapeutics' case rests on Food and Drug Administration (FDA) approval of ivonescimab in EGFR-mutant non-small cell lung cancer (NSCLC) by the 14 November 2026 goal date. AstraZeneca's $2.0 billion investment has covered funding. What remains open is how the agency reads a primary overall survival result with a p-value of 0.057. That decision settles the case.
The rating is Medium because the survival trend improved with longer follow-up and the shares no longer carry the pre-decision run-up. The goal date is a Saturday, so an action could be announced on or before Friday 13 November 2026. Company news and SEC filings show no FDA action, advisory committee or review extension through 12 November 2026.
The shares closed at $15.07 on 12 November 2026, after $17.84 on 9 November 2026 and $16.64 on 11 November 2026. No company disclosure or FDA statement accompanied the fall. At $15.07 the price sits below the $18.36 per-share equivalent AstraZeneca paid on 5 October 2026 and close to the $14.19 close of 5 November 2026, before the run. The market has given back its pre-decision gain and is pricing real doubt about approval.
Bullish and bearish views on Summit Therapeutics Inc.
The bull case on Summit Therapeutics Inc. (SMMT), in brief: survival trend improved with follow-up. The bear case: the primary survival result missed.
Bull case
- Survival trend improved with follow-up. Summit's 4 November 2026 release gives a June 2026 global HARMONi overall survival hazard ratio of 0.76 (95% confidence interval 0.61–0.95, nominal p=0.0151), against 0.79 (0.62–1.01, p=0.057) at the primary cut. Yahoo Finance reported median survival of 16.8 months with ivonescimab plus chemotherapy against 14.0 months with placebo plus chemotherapy.
- Western-patient results moved the right way. The Western-patient hazard ratio went from 0.98 to 0.84 to 0.76 across three data cuts, per Summit's 22 July 2026 release.
- Biliary survival benefit is statistically clear. HARMONi-GI1 reported a hazard ratio of 0.75 (95% CI 0.61–0.92, p=0.0031) against durvalumab plus chemotherapy in first-line biliary tract cancer, per Akeso's 25 October 2026 release. Summit opened a Phase II/III biliary trial with the ECOG-ACRIN group on 21 October 2026 to test this in Western patients.
- Funding risk has receded. AstraZeneca's $2.0 billion convertible preferred investment closed on 5 October 2026 at the equivalent of $18.36 per common share. Shareholders approved the authorized-share increase it needs on 4 November 2026, with 658,142,561 votes for and 1,983,511 against, per TipRanks.
- Bullish analysts held their ratings after the quarter. Stifel kept a Buy rating and cut its target to $37 from $38 on 5 November 2026, per Investing.com. Summit's third-quarter adjusted loss of $0.20 per share beat the $0.28 estimate on 4 November 2026, per Benzinga.
Bear case
- The primary survival result missed. Summit's 4 November 2026 release repeats the FDA's position that a statistically significant overall survival benefit is necessary to support approval in this setting. The primary p-value was 0.057; the 0.0151 from the June 2026 cut is nominal.
- Western evidence arrived late. The Western-patient hazard ratio was 0.98 at the first cut, per Summit's 22 July 2026 release. The improvement came from later cuts that the trial did not pre-specify as primary.
- First-line lung trial already stumbled. The HARMONi-3 squamous cohort missed an early survival mark at its 30 April 2026 interim analysis, per BioSpace. Its primary progression-free survival analysis is expected in Q4 2026.
- Losses still drive share sales. Summit reported a third-quarter GAAP net loss of $208.4 million and raised $94.1 million gross through at-the-market share sales in the quarter, per its 4 November 2026 8-K. Cash and short-term investments were $629.8 million at 30 September 2026, before the AstraZeneca money arrived.
- Sellers moved ahead of the decision. The shares fell from $17.84 on 9 November 2026 to $15.07 on 12 November 2026 with no company disclosure. On 11 November 2026, the day Summit closed at $16.64, Benzinga reported the Nasdaq 100 up 2.8%.
Price setup
The shares closed at $15.07 on 12 November 2026. That is 48.4% below the 52-week intraday high of $29.23 set on 21 April 2026, and above the 52-week closing low of $12.43 on 20 August 2026. The three-month change is 12.9%, from $13.35 on 14 August 2026.
The last close sits below both the 50-day moving average of $16.47 and the 200-day moving average of $16.15, as of 12 November 2026. The shares had moved above the 200-day average on 6 November 2026 and 9 November 2026 and gave that back over the next three sessions.
The levels the case turns on are the $14.19 close of 5 November 2026, the last close before the pre-decision run, and the $18.36 AstraZeneca conversion price above. An FDA action due by 14 November 2026 can move the shares well outside the range between them in either direction.
Catalysts ahead
- Q4 2026 (est.): HARMONi-3 squamous cohort primary progression-free survival analysis, with an early interim survival analysis. This cohort missed at its 30 April 2026 interim analysis. A second miss would weaken the Western path into first-line lung cancer.
- 31 December 2026: Deadline for AstraZeneca's preferred stock to convert into 108,955,369 common shares. The 4 November 2026 vote authorized the shares. A completed conversion closes the last open item on the $2.0 billion investment.
- H1 2027 (est.): HARMONi-3 non-squamous progression-free survival analysis. This is the next Western test of ivonescimab in first-line lung cancer after the FDA decision.
Elapsed catalysts
- 14 November 2026: FDA goal date for ivonescimab plus chemotherapy in EGFR-mutated non-squamous NSCLC after TKI therapy (a Saturday; action possible by 13 November 2026). Approval makes Summit a commercial company. A complete response letter or extension leaves a single-asset company with no approved product outside China. (passed)
What would change the view
A weekly close below $13.00, under the $14.19 close of 5 November 2026 and the $14.50 close of 26 October 2026, which would show the market pricing a failed review. An FDA complete response letter or review extension for ivonescimab would also break the approval case.
The risks this note tracks, each with what would confirm it:
- The FDA issues a complete response letter or extends its review, given a primary survival result of p=0.057 and its position that a statistically significant survival benefit is necessary. Confirmed by: an 8-K disclosing a complete response letter, a three-month extension, or an advisory committee called around 14 November 2026.
- Approval arrives with a restrictive label or a post-approval trial requirement, reducing its value as validation for larger lung cancer uses. Confirmed by: FDA-approved labeling or a company release after the decision showing narrower use than the application or new post-marketing obligations.
- HARMONi-3 squamous progression-free survival misses, repeating the 30 April 2026 interim result. Confirmed by: a topline release reporting a non-significant progression-free survival result in the squamous cohort.
- A rival PD-1/VEGF bispecific drug posts a clean Western Phase III lung-cancer win first. Confirmed by: a positive Phase III NSCLC topline from the Pfizer/3SBio or Bristol Myers Squibb/BioNTech programs.
- The biliary survival benefit does not carry over to Western patients, since HARMONi-GI1 ran only in China. Confirmed by: the ECOG-ACRIN Phase II/III biliary trial slipping, or an FDA position that China-only results cannot support a biliary filing.
- Spending growth leads to further share issuance even after the AstraZeneca funding. Confirmed by: further at-the-market proceeds in the Q4 2026 report, or a new equity offering after the FDA decision.
What it trades with
The shares trade on Summit-specific regulatory and trial news, with little link to the broad market around the decision. Summit fell on 11 November 2026 while the Nasdaq 100 rose 2.8%, per Benzinga. Benzinga's 9 November 2026 coverage tied the decision to the SPDR S&P Biotech ETF (XBI) and iShares Biotechnology ETF (IBB).
Akeso (HK: 9926) holds China rights to ivonescimab, so Akeso trial results and China approvals move Summit as read-through. Rival PD-1/VEGF bispecific programs from Pfizer/3SBio and Bristol Myers Squibb/BioNTech compete for the same lung cancer position, and a clean Western Phase III win by either would weigh on Summit. AstraZeneca's $2.0 billion stake ties Summit's funding to one large partner.
The evidence, claim by claim (8)
- The FDA goal action date for ivonescimab plus chemotherapy in EGFR-mutated non-squamous NSCLC after EGFR TKI therapy is 14 November 2026, and the FDA has said a statistically significant overall survival benefit is necessary in this setting. Summit Therapeutics Q3 2026 earnings release, Form 8-K, SEC EDGAR · as of
- Global HARMONi overall survival hazard ratio was 0.79 (95% CI 0.62-1.01, p=0.057) at the primary cut and 0.76 (95% CI 0.61-0.95, nominal p=0.0151) at the June 2026 cut. Summit Therapeutics Q3 2026 earnings release and 22 July 2026 HARMONi update · as of
- Summit held $629.8 million of cash and short-term investments at 30 September 2026, reported a GAAP net loss of $208.4 million, and raised $94.1 million gross through at-the-market share sales in the quarter. Summit Therapeutics Q3 2026 earnings release, Form 8-K, SEC EDGAR · as of
- Summit and AstraZeneca closed AstraZeneca's $2.0 billion convertible preferred investment, equivalent to $18.36 per share of common stock. Summit Therapeutics Q3 2026 earnings release, Form 8-K, SEC EDGAR · as of
- Shareholders approved the authorized-share increase needed for AstraZeneca's conversion, with 658,142,561 votes for and 1,983,511 against. TipRanks company announcement, 4 November 2026 · as of
- HARMONi-GI1 overall survival hazard ratio was 0.75 (95% CI 0.61-0.92, p=0.0031), with median survival of 14.9 vs 12.1 months against durvalumab plus chemotherapy in first-line biliary tract cancer. Akeso ESMO 2026 Presidential Symposium release, PR Newswire · as of
- Stifel maintained a Buy rating and cut its Summit Therapeutics price target to $37 from $38, citing valuation. Investing.com analyst report · as of
- Summit reported a third-quarter 2026 adjusted loss of $0.20 per share against a $0.28 consensus estimate. Benzinga earnings report · as of
Sources
- Summit Therapeutics Inc. - Form 8-K - FY2026 · sec.gov
- Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Po… · businesswire.com ·
- Summit Therapeutics Stockholders Approve Increase in Authorized Shares · tipranks.com ·
- Stifel cuts Summit Therapeutics stock price target on valuation · investing.com ·
- Summit shares descend as PD-1/VEGF asset misses early survival mark · biospace.com
- Summit Therapeutics shares advance after updated Phase III cancer trial results (NASDAQ:SMMT) · finance.yahoo.com
- Hims-Lilly GLP-1 Deal Meets Summit FDA Test: Biotech ETFs in Focus · benzinga.com
Related · shared themes
ZLAB
Zai Lab
Zai Lab's shares are modestly more likely to beat the S&P 500 over three months on zoci, its DLL3 cancer drug with an 81.8% first-line…
SLS
SELLAS Life Sciences Group
SELLAS Life Sciences is more likely to lag the S&P 500 over three months: its value rests on one Phase 3 leukemia trial, REGAL, whose…
CORT
Corcept Therapeutics
Corcept Therapeutics' Lifyorli launch is compounding ($91.4 million in Q3 2026, up from $47.6 million in Q2), yet the shares sit near their…
ELVN
Enliven Therapeutics
Enliven Therapeutics is modestly more likely than not to beat the S&P 500 over three months: $884.4 million in cash and FDA alignment fund…
See also · stocks to watch